Search - tctmd.com

Displaying 501 - 520 of 829

Sort: Relevancy | Date

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

February 26, 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

News Conference News ISC 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

February 25, 2020

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

February 14, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

Aspirin Not Protective Against CVD in Black Patients

News Daily News

Aspirin Not Protective Against CVD in Black Patients

December 18, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Grief and CVD: Simple Regimen May Lower Risk

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

November 19, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.